1.14.99.1 1,10-phenanthroline weak 62 1.14.99.1 1-Mercapto-9,11,15-trihydroxyprosta-5,13-diene inhibition of prostaglandin G1 synthesis 90540 1.14.99.1 1-Mercapto-9-oxo-11,15-dihydroxyprosta-5,13-dione inhibition of prostaglandin G1 synthesis 90541 1.14.99.1 12-nitroarachidonic acid nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase and peroxidase activity PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation 194323 1.14.99.1 14-nitroarachidonic acid nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase and peroxidase activity PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation 194324 1.14.99.1 15-nitroarachidonic acid nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase and peroxidase activity PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation 194325 1.14.99.1 2,2'-bipyridyl weak 1706 1.14.99.1 2,3-Dimercaptopropanol inhibition of prostaglandin G1 synthesis 2535 1.14.99.1 2-hydroxybutyric acid weak 15496 1.14.99.1 3,6-bis(3-[[(furan-2-yl)methyl]amino]propyl)-9H-xanthen-9-one - 222505 1.14.99.1 3,6-bis(5-[[(furan-2-yl)methyl]amino]pentyl)-9H-xanthen-9-one - 222519 1.14.99.1 3,6-bis[3-(2-methyl-1H-indol-1-yl)propyl]-9H-xanthen-9-one - 222502 1.14.99.1 3,6-bis[3-(4-methylpiperazin-1-yl)propyl]-9H-xanthen-9-one - 222503 1.14.99.1 3,6-bis[3-(4-nitroanilino)propyl]-9H-xanthen-9-one - 222506 1.14.99.1 3,6-bis[3-(cyclohexylamino)propyl]-9H-xanthen-9-one - 222504 1.14.99.1 3,6-bis[3-(morpholin-4-yl)propyl]-9H-xanthen-9-one - 222507 1.14.99.1 3,6-bis[3-(piperidin-1-yl)propyl]-9H-xanthen-9-one - 222501 1.14.99.1 3,6-bis[3-[(1H-pyrazol-3-yl)amino]propyl]-9H-xanthen-9-one - 222495 1.14.99.1 3,6-bis[3-[(2-chloropyridin-3-yl)amino]propyl]-9H-xanthen-9-one - 222508 1.14.99.1 3,6-bis[3-[(4H-1,2,4-triazol-4-yl)amino]propyl]-9H-xanthen-9-one - 224513 1.14.99.1 3,6-bis[3-[(pyrazin-2-yl)amino]propyl]-9H-xanthen-9-one - 222497 1.14.99.1 3,6-bis[3-[(pyridin-2-yl)amino]propyl]-9H-xanthen-9-one - 222500 1.14.99.1 3,6-bis[4-(1H-imidazol-2-yl)butyl]-9H-xanthen-9-one - 222498 1.14.99.1 3,6-bis[5-(2-methyl-1H-indol-1-yl)pentyl]-9H-xanthen-9-one - 222516 1.14.99.1 3,6-bis[5-(4-methylpiperazin-1-yl)pentyl]-9H-xanthen-9-one - 222517 1.14.99.1 3,6-bis[5-(4-nitroanilino)pentyl]-9H-xanthen-9-one - 222522 1.14.99.1 3,6-bis[5-(cyclohexylamino)pentyl]-9H-xanthen-9-one - 222518 1.14.99.1 3,6-bis[5-(morpholin-4-yl)pentyl]-9H-xanthen-9-one - 222520 1.14.99.1 3,6-bis[5-(piperidin-1-yl)pentyl]-9H-xanthen-9-one - 222515 1.14.99.1 3,6-bis[5-[(1H-pyrazol-3-yl)amino]pentyl]-9H-xanthen-9-one - 222509 1.14.99.1 3,6-bis[5-[(2-chloropyridin-3-yl)amino]pentyl]-9H-xanthen-9-one - 222521 1.14.99.1 3,6-bis[5-[(4H-1,2,4-triazol-4-yl)amino]pentyl]-9H-xanthen-9-one - 222513 1.14.99.1 3,6-bis[5-[(piperidin-1-yl)amino]pentyl]-9H-xanthen-9-one - 222510 1.14.99.1 3,6-bis[5-[(pyrazin-2-yl)amino]pentyl]-9H-xanthen-9-one - 222511 1.14.99.1 3,6-bis[5-[(pyridin-2-yl)amino]pentyl]-9H-xanthen-9-one - 222514 1.14.99.1 3,6-bis[6-(1H-imidazol-2-yl)hexyl]-9H-xanthen-9-one - 222512 1.14.99.1 5,8,11,14-Eicosatetraynoic acid complete inhibition at 0.04 mM 4214 1.14.99.1 5,8,11,14-Eicosatetraynoic acid - 4214 1.14.99.1 5-amino-2-hydroxy-N-(propan-2-yl)benzamide 5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 7.6fold selectivity for isoform Cox-2 over Cox-1 261559 1.14.99.1 5-amino-N-cyclohexyl-2-hydroxybenzamide 5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 44fold selectivity for isoform Cox-2 over Cox-1 261561 1.14.99.1 5-amino-N-hexyl-2-hydroxybenzamide 5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 44fold selectivity for isoform Cox-2 over Cox-1 261562 1.14.99.1 5-bromo-2-[4-fluorophenyl]-3-[4-methylsulfonylphenyl]-thiophene DuP-697, selective for isozyme 2 49844 1.14.99.1 5-bromo-2-[4-fluorophenyl]-3-[4-methylsulfonylphenyl]-thiophene 50% inhibition at 8.7 nM 49844 1.14.99.1 5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-N-(4-methylphenyl)benzamide 5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 29.7fold selectivity for isoform Cox-2 over Cox-1 261602 1.14.99.1 6-methoxy-2-naphthyl acetic acid active metabolite of nabumetone, isozyme 1, 50% inhibition at 0.2-0.8 mM, isozyme 2, 50% inhibition at 0.015-0.55 mM 108578 1.14.99.1 6-methylnaphthylacetic acid recombinant protein, 50% inhibition at 0.08-0.1 mM 108582 1.14.99.1 6-[2,4-difluorophenoxy]-5-methyl-sulfonylamino-1-indanone CGP28238, an isozyme-2 specific inhibitor, 65% inhibition at 100 nM 108557 1.14.99.1 8-hydroxyquinoline - 321 1.14.99.1 9,11-Dihydroxy-15S-mercaptoprosta-5,13-dienoic acid or 15R-isomer, inhibition of prostaglandin G1 synthesis 92151 1.14.99.1 9-nitroarachidonic acid nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase activity and peroxidase activity of PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation 194322 1.14.99.1 acetoacetic acid weak 10562 1.14.99.1 Acetylsalicylic acid inhibition of prostaglandin G1 synthesis 2261 1.14.99.1 Acetylsalicylic acid inhibition of oxygenase activity by acetylating a serine residue of the enzyme 2261 1.14.99.1 Acetylsalicylic acid isozyme 1, complete inhibition, isozyme 2, change in reaction, main product from arachidonate is 15-hydroxyeicosatetraenoic acid 2261 1.14.99.1 Acetylsalicylic acid - 2261 1.14.99.1 Acetylsalicylic acid irreversible inhibitor 2261 1.14.99.1 Acetylsalicylic acid an irreversible inhibitor of both hPHS-1 and hPHS-2 2261 1.14.99.1 albumin - 1519 1.14.99.1 albumin bovine serum albumin inhibits by binding of arachidonic acid 1519 1.14.99.1 alpha-linolenic acid - 2620 1.14.99.1 anirolac isozyme 1, 50% inhibition at 0.0007 mM, isozyme 2, 50% inhibition at 0.009 mM 108688 1.14.99.1 aspirin - 3100 1.14.99.1 aspirin cyclooxygenase activity 3100 1.14.99.1 azide weak 230 1.14.99.1 bicarbonate bicarbonate enhances peroxynitrite-mediated peroxidase inactivation 1136 1.14.99.1 Butyric acid - 1556 1.14.99.1 BW 755C recombinant protein, 50% inhibition at 0.01-0.02 mM 108754 1.14.99.1 celecoxib - 1809 1.14.99.1 crotonic acid - 7172 1.14.99.1 cyanide - 118 1.14.99.1 DCM-extract of Angelicae dahuricae radix 0.1% inhibition of PGHS-1; 38.8% inhibition of PGHS-2 62215 1.14.99.1 DCM-extract of Angelicae sinsesis radix 55.8% inhibition of PGHS-2; 75.0% inhibition of PGHS-1 62216 1.14.99.1 DCM-extract of Atractylodis lanceae rhizoma 46.9% inhibition of PGHS-1; 50.3% inhibition of PGHS-2 62217 1.14.99.1 DCM-extract of Atractylodis macrocephalae rhizoma 47.0% inhibition of PGHS-2; 58.6% inhibition of PGHS-1 62218 1.14.99.1 DCM-extract of Cinnamomi ramulus 48.4% inhibition of PGHS-2; 73.5% inhibition of PGHS-1 62219 1.14.99.1 DCM-extract of Houttuyniae herba 40.9% inhibition of PGHS-2; 46.8% inhibition of PGHS-1 62220 1.14.99.1 DCM-extract of Notopterygii rhizoma seu radix -2.1% inhibition of PGHS-2; 42.6% inhibition of PGHS-1 62221 1.14.99.1 DCM-extract of Piperis sarmentosi herba 10.1% inhibition of PGHS-2; 47.2% inhibition of PGHS-1 62222 1.14.99.1 DCM-extract of Platycodi radix 70.1% inhibition of PGHS-2; 77.8% inhibition of PGHS-1 62223 1.14.99.1 DCM-extract of Zanthoxyli pericarpium 18.3% inhibition of PGHS-1; 31.3% inhibition of PGHS-2 62224 1.14.99.1 DCM-extract of Zingiberis rhizoma 41.3% inhibition of PGHS-2; 52.9% inhibition of PGHS-1 62225 1.14.99.1 delta-tocopherol-13'-carboxychromanol inhibits isoform Cox-1 and suppresses Cox-1 mediated formation of thromboxane in collagen-stimulated rat's platelets 262283 1.14.99.1 delta-tocotrienol inhibits isoform Cox-1 and suppresses Cox-1 mediated formation of thromboxane in collagen-stimulated rat's platelets 84180 1.14.99.1 delta-tocotrienol-13'-carboxychromanol inhibits isoform Cox-1 and suppresses Cox-1 mediated formation of thromboxane in collagen-stimulated rat's platelets 262284 1.14.99.1 diclofenac recombinant protein, 50% inhibition at 0.04 mM 1291 1.14.99.1 diclofenac 50% inhibition at 9.4 nM 1291 1.14.99.1 diclofenac isozyme 1, 50% inhibition at 0.0009 mM, isozyme 2, 50% inhibition at 0.0015 mM 1291 1.14.99.1 diclofenac isozyme 1, 50% inhibition at 0.0003 mM, isozyme 2, 50% inhibition at 18 nM 1291 1.14.99.1 diethyldithiocarbamate - 373 1.14.99.1 dihydrolipoic acid inhibition of prostaglandin G1 synthesis 3464 1.14.99.1 dithiothreitol inhibition of prostaglandin G1 synthesis 45 1.14.99.1 DL-Propanolol - 45500 1.14.99.1 docosahexaenoic acid isozyme 1, 50% inhibition at 0.011 mM, isozyme 2, 50% inhibition at 0.015 mM 4947 1.14.99.1 DUP-697 a standard PHS-2 inhibitor 85035 1.14.99.1 DUP-697 a PHS-2-specific inhibitor 85035 1.14.99.1 EDTA weak 21 1.14.99.1 EGTA weak 173 1.14.99.1 Eicosa-5,8,11,14-tetraynoic acid - 44102 1.14.99.1 ellagic acid at high concentration and in presence of cofactors inhibition, at low concentrations stimulation 1279 1.14.99.1 etodalac recombinant protein, 50% inhibition at 0.06-0.07 mM 108936 1.14.99.1 ETYA recombinant protein, 50% inhibition at 0.015-0.025 mM 108937 1.14.99.1 fatty acid of low molecular mass 833 1.14.99.1 fenclofenac isozyme 1, 50% inhibition at 0.007 mM, isozyme 2, 50% inhibition at 0.004 mM 108955 1.14.99.1 flosulide selective for isozyme 2, 50% inhibition at 130 nM 108971 1.14.99.1 Flufenamic acid 50% inhibition at 0.02 mM 2022 1.14.99.1 flurbiprofen isozyme 1, 50% inhibition at 40 nM, isozyme 2, 50% inhibition at 500 nM 3816 1.14.99.1 flurbiprofen isozyme 1, 50% inhibition at 0.0009 mM, isozyme 2, 50% inhibition at 0.0009 mM 3816 1.14.99.1 flurbiprofen isozyme 1, 50% inhibition at 0.0005 mM, isozyme 2, 50% inhibition at 0.003 mM 3816 1.14.99.1 flurbiprofen cyclooxygenase inhibitor 3816 1.14.99.1 Haptoglobin - 16294 1.14.99.1 Human serum - 10968 1.14.99.1 Ibuprofen recombinant protein, 50% inhibition at 0.04 mM 1645 1.14.99.1 Ibuprofen reversible 1645 1.14.99.1 Ibuprofen 50% inhibition at 0.253 mM 1645 1.14.99.1 Ibuprofen isozyme 1, 50% inhibition at 0.0026 mM, isozyme 2, 50% inhibition at 0.0015 mM 1645 1.14.99.1 Ibuprofen isozyme 1, 50% inhibition at 0.009 mM, isozyme 2, 50% inhibition at 0.018 mM 1645 1.14.99.1 Ibuprofen isozyme 1, 50% inhibition at 0.09 mM, isozyme 2, 50% inhibition at 0.008 mM 1645 1.14.99.1 indomethacin inhibition of prostaglandin G1 synthesis 546 1.14.99.1 indomethacin - 546 1.14.99.1 indomethacin acts on isozyme 1 and 2, 85% inhibition at 100 nM 546 1.14.99.1 indomethacin reversible and time-dependent inhibition 546 1.14.99.1 indomethacin 50% inhibition at 100 nM 546 1.14.99.1 indomethacin isozyme 1, 50% inhibition at 0.0017 mM, isozyme 2, 50% inhibition at 0.025 mM 546 1.14.99.1 indomethacin inhibition in gastrointestinal tissues 546 1.14.99.1 indomethacin isozyme 1 50% inhibition at 0.0005 mM, isozyme 2, 50% inhibition at 0.0003 mM 546 1.14.99.1 indomethacin isozyme 1, 50% inhibition at 0.005 mM, isozyme 2, 50% inhibition at 0.130-0.160 mM 546 1.14.99.1 Ketoprofen isozyme 1, 50% inhibition at 0.0005 mM, isozyme 2, 50% inhibition at 0.0025 mM 3079 1.14.99.1 Ketoprofen isozyme 1, 50% inhibition at 0.011 mM, isozyme 2, 50% inhibition at 0.018 mM 3079 1.14.99.1 L-745 isozyme 1, 50% inhibition at 0.369 mM, isozyme 2, 50% inhibition at 0.002 mM 109083 1.14.99.1 linoleic acid - 428 1.14.99.1 Meclofenamic acid - 5993 1.14.99.1 Meclofenamic acid isozyme 1, 50% inhibition at 0.002 mM, isozyme 2, 50% inhibition at 0.015 mM 5993 1.14.99.1 Mefenamic acid isozyme 1, 50% inhibition at 0.01 mM, isozyme 2, 50% inhibition at 0.0003 mM 2086 1.14.99.1 meloxicam isozyme 1, 50% inhibition at 0.005 mM, isozyme 2, 50% inhibition at 0.0004 mM 5320 1.14.99.1 additional information effect of cofactor, enzyme and substrate concentration on inhibition by human serum, haptoglobin and albumin 2 1.14.99.1 additional information mechanism of selective inhibition 2 1.14.99.1 additional information nimesulide inhibits PGHS-2 turnover in most brain regions 2 1.14.99.1 additional information guava leaf extract inhibits the catalytic activity of the PGHS-1 isoform using linoleic acid as substrate (IC50 value of 0.055 mg of dry leaf extract); guava leaf extract inhibits the catalytic activity of the PGHS-2 isoform using linoleic acid as substrate (IC50 value of 0.56 mg of dry leaf extract); isozyme PGHS-1 is hardly inhibited by ellagic acid; isozyme PGHS-2 is hardly inhibited by ellagic acid 2 1.14.99.1 additional information guava leaf extract inhibits the catalytic activity of the PGHS-1 and PGHS-2 isoforms using linoleic acid as substrate; guava leaf extract inhibits the catalytic activity of the PGHS-1 and PGHS-2 isoforms using linoleic acid as substrate; isozyme PGHS-1 is hardly inhibited by ellagic acid; isozyme PGHS-2 is hardly inhibited by ellagic acid 2 1.14.99.1 additional information algal PGHS is not inhibited by non-steroidal anti-inflammatory drugs that inhibit the mammalian enzymes 2 1.14.99.1 additional information no inhibition of PGHS-2 oxygenase activity by 9-nitro-, 12-nitro-, 14-nitro, and 15-nitroarachidonic acid and by nitrooleic acid and nitrolinoleic acid; other nitro fatty acids tested, such as nitrooleic acid and nitrolinoleic acid, are unable to inhibit the enzyme activity 2 1.14.99.1 N-butyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide 5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 135fold selectivity for isoform Cox-2 over Cox-1 261990 1.14.99.1 N-cyclohexyl-5-[(E)-[(2,5-dihydroxyphenyl)methylidene]amino]-2-hydroxybenzamide 5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 120fold selectivity for isoform Cox-2 over Cox-1 261991 1.14.99.1 N-cyclohexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide 5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 114fold selectivity for isoform Cox-2 over Cox-1 261992 1.14.99.1 n-hexane extract of Angelicae dahuricae radix 42.4% inhibition of PGHS-2; 52.5% inhibition of PGHS-1 62204 1.14.99.1 n-hexane extract of Angelicae sinsesis radix 61.5% inhibition of PGHS-2; 73.0% inhibition of PGHS-1 62205 1.14.99.1 n-hexane extract of Atractylodis lanceae rhizoma 67.4% inhibition of PGHS-1; 68.3% inhibition of PGHS-2 62206 1.14.99.1 n-hexane extract of Atractylodis macrocephalae rhizoma 46.1% inhibition of PGHS-1; 48.9% inhibition of PGHS-2 62207 1.14.99.1 n-hexane extract of Cinnamomi ramulus 23.6% inhibition of PGHS-2; 46.6% inhibition of PGHS-1 62208 1.14.99.1 n-hexane extract of Houttuyniae herba 43.4% inhibition of PGHS-2; 50.3% inhibition of PGHS-1 62209 1.14.99.1 n-hexane extract of Notopterygii rhizoma seu radix 64.9% inhibition of PGHS-2; 69.6% inhibition of PGHS-1 62210 1.14.99.1 n-hexane extract of Piperis sarmentosi herba 52.4% inhibition of PGHS-1; 65.0% inhibition of PGHS-2 62211 1.14.99.1 n-hexane extract of Platycodi radix 48.7% inhibition of PGHS-1; 55.1% inhibition of PGHS-2 62212 1.14.99.1 n-hexane extract of Zanthoxyli pericarpium 24.9% inhibition of PGHS-2; 48.5% inhibition of PGHS-1 62213 1.14.99.1 n-hexane extract of Zingiberis rhizoma 77.5% inhibition of PGHS-2; 83.4% inhibition of PGHS-1 62214 1.14.99.1 N-hexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide 5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 145fold selectivity for isoform Cox-2 over Cox-1 261993 1.14.99.1 N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide NS-398, selective for isozyme 2 8449 1.14.99.1 N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide 50% inhibition at 81 nM 8449 1.14.99.1 N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide isozyme 1, 50% inhibition at 0.075 mM, isozyme 2, 50% inhibition at 0.002 mM 8449 1.14.99.1 N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide little inhibition in gastrointestinal tissues 8449 1.14.99.1 N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide isozyme 1, 50% inhibition at 0.017 mM, isozyme 2, 50% inhibition at 0.0001 mM 8449 1.14.99.1 naproxen recombinant protein, 50% inhibition at 0.05-0.06 mM 1792 1.14.99.1 naproxen isozyme 1, 50% inhibition at 0.0006 mM, isozyme 2, 50% inhibition at 0.002 mM 1792 1.14.99.1 naproxen inhibitor of cyclooxigenase reaction; inhibitor of cyclooxigenase reaction 1792 1.14.99.1 naproxen - 1792 1.14.99.1 niflumic acid isozyme 1, 50% inhibition at 0.016 mM, isozyme 2, 50% inhibition at 0.0001 mM 7456 1.14.99.1 nimesulide isozyme 1, 50% inhibition at 0.07 mM, isozyme 2, 50% inhibition at 0.0013 mM 4345 1.14.99.1 nimesulide isozyme 1, 50% inhibition at 0.009 mM, isozyme 2, 50% inhibition at 0.0005 mM 4345 1.14.99.1 nimesulide - 4345 1.14.99.1 nimesulide inhibits the cyclooxygenase activity, a COX-2-specific inhibitor 4345 1.14.99.1 Non-steroidal anti-inflammatory agents inhibition of cyclooxygenase activity 46840 1.14.99.1 NS-398 - 5807 1.14.99.1 NS-398 inhibits PTGS2 5807 1.14.99.1 NS398 - 224512 1.14.99.1 O2 the cyclooxygenase reaction is inhibited by an excess of dissolved oxygen, 0.5 mM O2 causes twofold decrease in the initial rate and maximal yield 9 1.14.99.1 oleic acid - 380 1.14.99.1 p-Aminophenol - 7265 1.14.99.1 PD-98059 MEK inhibitor, blocks specifically the activation of ERK1/2 and the PGHS-2 mRNA response to oxygen and glucose depivation, hence ERK is a mediator of PGHS-2 gene expression 23057 1.14.99.1 peroxynitrite - 1220 1.14.99.1 piroxicam isozyme 1, 50% inhibition at 0.009-0.024 mM, isozyme 2, 50% inhibition at 0.070-0.240 mM 4121 1.14.99.1 piroxicam isozyme 1, 50% inhibition at 0.075 mM, isozyme 2, 50% inhibition at 0.002 mM 4121 1.14.99.1 propionic acid - 1724 1.14.99.1 quercetin - 137 1.14.99.1 quercetin 3-O-glucoside - 4048 1.14.99.1 SB203580 inhibitor of p38, reduces the PGHS-2 response to oxygen and glucose depivation by approximately 50% 1808 1.14.99.1 SC-560 a standard PHS-1 inhibitor 18639 1.14.99.1 SC-560 a PHS-1-specific inhibitor 18639 1.14.99.1 SC58125 isozyme 1, 50% inhibition at 0.039 mM, isozyme 2, 50% inhibition at 0.0003 mM 109575 1.14.99.1 sulindac sulfide isozyme 1, 50% inhibition at 0.0004 mM, isozyme 2, 50% inhibition at 0.012 mM 3533 1.14.99.1 suprofen isozyme 1, 50% inhibition at 0.0005 mM, isozyme 2, 50% inhibition at 0.002mM 109614 1.14.99.1 Tannic acid at high concentration and in presence of cofactors inhibition, at low concentrations stimulation 1019 1.14.99.1 U0126 MEK inhibitor, blocks specifically the activation of ERK1/2 and the PGHS-2 mRNA response to oxygen and glucose depivation, hence ERK is a mediator of PGHS-2 gene expression 2692 1.14.99.1 valeryl salicylate - 135269